Want to see HK:2393 full AI Analyst Report?
2393 Stock Chart & Stats
HK$0.06
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$0.06
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.04 - HK$0.17
Previous CloseN/A
Volume70.00K
Average Volume (3M)227.50K
Market Cap
HK$153.76M
Enterprise ValueHK$177.64
Total Cash (Recent Filing)HK$194.45M
Total Debt (Recent Filing)HK$202.47M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.02%
Share Statistics
EPS (TTM)-0.04
Shares Outstanding2,331,590,000
10 Day Avg. Volume125,990
30 Day Avg. Volume227,496
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)0.14
P/FCF Ratio0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetLower debt and restored positive equity materially reduce balance-sheet strain compared with 2021–2023. Moderate leverage gives Yestar greater financial flexibility to sustain clinic operations, absorb weaker demand, and allocate capital without relying as heavily on additional borrowing.
Strong 2025 Cash GenerationThe sharp rebound in operating and free cash flow indicates that the business converted activity into cash effectively in 2025, even while reporting a net loss. Stronger internal cash generation can support clinic investment, working capital needs, and financial resilience over coming quarters.
Direct Clinic Service ModelA branded clinic network with services delivered by in-house professionals gives Yestar a direct operating platform for patient relationships and service revenue. The model can support repeat treatments, procedure mix development, and utilization improvement as clinics serve elective healthcare demand.
Bears Say
Sharp Revenue ContractionA steep top-line decline signals weakened demand or clinic activity and reduces the revenue base available to cover fixed operating costs. Unless volumes recover, sustained contraction can limit scale benefits, constrain investment capacity, and make future earnings improvement more difficult.
Return To Net LossThe return to a net loss shows that reported earnings remain fragile despite positive operating profit. Persistent losses would weaken retained equity and reduce the funds available for clinic expansion, while also indicating that the current operating model has not yet produced stable shareholder returns.
Volatile Cash-flow DurabilityAlthough 2025 cash generation was strong, the history of negative or weak cash flow shows that conversion is not consistently resilient through the cycle. This volatility may complicate planning and make funding for operations or growth more dependent on future business conditions.
Yestar Healthcare Holdings Co Ltd News
2393 FAQ
What was Yestar Healthcare Holdings Co Ltd’s price range in the past 12 months?
Yestar Healthcare Holdings Co Ltd lowest stock price was HK$0.04 and its highest was HK$0.17 in the past 12 months.
What is Yestar Healthcare Holdings Co Ltd’s market cap?
Yestar Healthcare Holdings Co Ltd’s market cap is HK$153.76M.
When is Yestar Healthcare Holdings Co Ltd’s upcoming earnings report date?
Yestar Healthcare Holdings Co Ltd’s upcoming earnings report date is Mar 26, 2027 which is in 185 days.
How were Yestar Healthcare Holdings Co Ltd’s earnings last quarter?
Yestar Healthcare Holdings Co Ltd released its earnings results on Aug 28, 2026. The company reported -HK$0.002 earnings per share for the quarter.
Is Yestar Healthcare Holdings Co Ltd overvalued?
According to Wall Street analysts Yestar Healthcare Holdings Co Ltd’s price is currently Overvalued.
Does Yestar Healthcare Holdings Co Ltd pay dividends?
Yestar Healthcare Holdings Co Ltd pays a Annually dividend of HK$0.055 which represents an annual dividend yield of 2.02%. See more information on Yestar Healthcare Holdings Co Ltd dividends here
What is Yestar Healthcare Holdings Co Ltd’s EPS estimate?
Yestar Healthcare Holdings Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yestar Healthcare Holdings Co Ltd have?
Yestar Healthcare Holdings Co Ltd has 2,331,590,000 shares outstanding.
What happened to Yestar Healthcare Holdings Co Ltd’s price movement after its last earnings report?
Yestar Healthcare Holdings Co Ltd reported an EPS of -HK$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Yestar Healthcare Holdings Co Ltd?
Currently, no hedge funds are holding shares in HK:2393
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yestar Healthcare Holdings Co Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Yestar Healthcare Holdings Co Ltd
Yestar Healthcare Holdings Company Limited, an investment holding company, manufactures, distributes, and sells medical imaging products in Mainland China. The company operates in two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells color photographic paper and industrial NDT x-ray films and PWB films, as well as trades in imaging equipment. The Medical Products and Equipment segment manufactures and sells medical dry, medical wet, and dental films, as well as sells medical equipment and diagnostic reagents. The company also engages in the management of supply chain and service of freight transportation equipment, as well as development of biotechnology. The company was formerly known as Yestar International Holdings Company Limited and changed its name to Yestar Healthcare Holdings Company Limited in January 2017. Yestar Healthcare Holdings Company Limited was founded in 1971 and is headquartered in Shanghai, the People’s Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
Acotec Scientific Holdings Limited
―
Vincent Medical Holdings Limited
―
Sisram Medical Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―